Cycle or Swap? The swap strategy (SG) (i.e. from TNFi to IL17i) had higher retention rates compared to the change strategy (CG) choice in PsA patients who failed the first line of advanced treatment. The 5 years retention rate in SG was higher than in CG (57,8% vs 45,2%; p=0.1).… https://t.co/pH5rFI00vK https://t.co/XqTHO1tIr3

• https://twitter.com/i/web/status/1801585922292519240
• https://twitter.com/synovialjoints/status/1801585922292519240/photo/1
• https://twitter.com/synovialjoints/status/1801585922292519240/photo/1

Discovery in joint and skin disease - PsA Three different clusters #EULAR2024 @RheumNow https://t.co/Nj5HZOVqas

• https://twitter.com/bella_mehta/status/1801584877097336910/photo/1

The age old question in #inflammatory #arthritis Should you cycle within TNFi class or move on to another MOA in #PsA #psoriatic #arthritis Better retention to go to a IL17i vs another TNFi in observational study comparing the 2 POS0266 #EULAR2024 @RheumNow @eular_org https://t.co/CXcmYAG4m9

• https://twitter.com/Janetbirdope/status/1801582359914897665/photo/1
• https://twitter.com/Janetbirdope/status/1801582359914897665/photo/1

Can you predict which pts with #PsA #psoriatic #arthritis Will respond to #TNFi #Rx? Well, 🤔 maybe Needs validation and an easy reliable inexpensive biomarker! #EULAR2024 @RheumNow @eular_org POS0992 https://t.co/Ce92561AMO

• https://twitter.com/Janetbirdope/status/1801580319641874565/photo/1
• https://twitter.com/Janetbirdope/status/1801580319641874565/photo/1

PsA: one composite index that does it all cDAPSA + Investigator’s Global Assessment (IGA) of PSO Cohen’s kappa 0.72 & 88% concordance with PASDAS LDA 88% sensitivity & specificity in DISCOVER-1 & 2 trial data #EULAR2024 @RheumNow POS0254 https://t.co/ZBb1M4IusC

• https://twitter.com/AurelieRheumo/status/1801513887650435431/photo/1

🚨 New 68Ga-FAPI-04-PET/CT, fibroblast activation tracer 38 PSO patients w/ arthralgia Correlation PET/CT SUVmax, TJC & tender enthesis count 68Ga-FAPI-04 uptake = higher risk developing PsA 6mo Shows signs of inflammation before MSUS! #EULAR2024 @RheumNow POS0242 https://t.co/GG6qeD4qJn

• https://twitter.com/AurelieRheumo/status/1801509983638507885/photo/1

This can be coming to a clinic near you. Hotspot/ROI ratio (HRR) values from high-resolution thermographic marker in the detection of joint inflammation, compared to joint ultrasound showed excellent performance in the differentiation of joints with US inflammatory activity from… https://t.co/1unRxxgHAd https://t.co/tOPDSxzvwB

• https://twitter.com/i/web/status/1801510391878398397
• https://twitter.com/synovialjoints/status/1801510391878398397/photo/1

Did the patient fail on therapy or are the therapies failing the patient? 🤔 Difficult to to manage psoriatic arthritis: A suggested approach #EULAR2024 NZ https://t.co/lYvXEX7dp3

• https://twitter.com/ARD_BMJ/status/1800873396042924158/photo/1

New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated. Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA IH https://t.co/RvcONHCLvz

• https://twitter.com/ARD_BMJ/status/1801179294271443086/photo/1

Swedish/Danish cohort study in PsA 17000+ bionaïve 8000+ TNFi & 2000+ other MoA Overall non melanoma skin cancer rate 651 (505 BCC & 87 SCC) TNFi treated pts: HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50) HR 1.19 NMSC vs. other MoA (ns) #EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6

• https://twitter.com/AurelieRheumo/status/1801230838136213897/photo/1

TYK2i RCT 290 pts 12 wks in active PSA TAK-279 15mg 30 mg 53% 54% vs PBO 29% ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15% Safety profile acceptable Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp

• https://twitter.com/AurelieRheumo/status/1801228048466870716/photo/1

12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB

• https://twitter.com/i/web/status/1801191845084463335
• https://twitter.com/synovialjoints/status/1801191845084463335/photo/1
• https://twitter.com/synovialjoints/status/1801191845084463335/photo/1

Combination of GOL/MTX was not significantly superior in reducing PASDAS-measured disease activity at 24 weeks. First line treatment of early, DMARD naïve PsA with MTX 25 mg/week and CS produced effective disease control. There was low utilisation of bDMARDs at 52 weeks in both… https://t.co/aEg9rw4evM https://t.co/prDtnHm793

• https://twitter.com/i/web/status/1801188741400109274
• https://twitter.com/synovialjoints/status/1801188741400109274/photo/1